Case report demonstrates application of autologous bone marrow and ultrasound guidance in POI treatment.
Premature ovarian insufficiency (POI) is a clinical syndrome characterized by an early loss of ovarian function, manifested by menstrual irregularity or amenorrhea with elevated levels of gonadotrophin hormones and low levels of estrogen and anti-Mullerian hormones. Regenerative medicine treats a variety of diseases by using cells or biological products instead of conventional drugs or other interventions. The autologous use of stem cells from bone marrow or adipose tissue (stromal vascular fraction) or growth factor products such as platelet-rich plasma are safe alternative minimally manipulated products that can potentially solve this clinical problem without an oocyte donation program. The current study reports the application of regenerative medicine: autologous bone marrow aspirate concentrate is used to treat premature ovarian insufficiency using minimal manipulation combined with minimal surgical intervention through an intravaginal approach under ultrasound guidance. In conclusion, to the authors' knowledge, this is the first case study that reports the treatment of ROI via a transvaginal approach in delivering bone marrow aspirate concentrate.
No takes yet. Share an insight, caveat, or question.
Hammadi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: